Target expression details
Target General Information | |||||
---|---|---|---|---|---|
Target ID | T54902 | ||||
Target Name | MHC class I NK cell receptor | ||||
Synonyms | CD158 antigenlike family member B1; Killer cell immunoglobulinlike receptor 2DL2; MHC class I NK cell receptor; NKAT6; Natural killerassociated transcript 6; p58 NK receptor CL43; p58 natural killer cell receptor clone CL43; KIR2DL2 | ||||
Target Type | Clinical Trial | ||||
Gene Name | KIR2DL2 | ||||
Biochemical Class | Immunoglobulin | ||||
UniProt ID | KI2L2_HUMAN | ||||
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
Disease | Myeloma | ||||
Example drug | mab 1-7F9 | Phase 2 | [530228], [530238], [1572592] | ||
Tissue | Bone marrow | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.93 Z-score: -3.58 P-value: 1.69E-05 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
Disease | Acute myelocytic leukemia | ||||
Tissue | Bone marrow | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.58 Z-score: -1.03 P-value: 5.32E-23 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
Reference | |||||
Ref 530228 | Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009 Sep 24;114(13):2667-77. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.